{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:38:23Z","timestamp":1792643903604,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Myasthenia gravis (MG) is a chronic neuromuscular disease. Advances in medical therapy have continuously increased the life expectancy of MG patients, without definitively curing the disease. To analyze life circumstances and quality of life (QoL), a large German MG cohort was investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and Sample<\/jats:title><jats:p>In cooperation with the German Myasthenia Association, 2,150 patients with confirmed MG were asked to respond to a mailed questionnaire. The standardized questions related to demographic data, impairments, therapeutic course, use of complementary therapies, illness-related costs, and quality of life (SF-36). In total, 1,518 patients participated, yielding a response rate of 70.6%. The average age was 56.7 years, and the proportion of females 58.6%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Despite receiving recommended therapy, many patients still suffered from MG-related impairments. In particular, mobility and mental well-being were reduced; moreover, quality of life was markedly reduced. Stepwise linear regression analysis revealed illness stability, impairments, mental conditions, comorbid diseases, and employment to be determinants of QoL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Results indicate that despite prolonged life expectancy among MG patients, health-related quality of life is low. This outcome resulted mainly from impaired mobility and depression. Physical and mental well-being might be improved by additional therapy options. Additionally, health care resources could be used more efficiently in these patients.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1477-7525-8-129","type":"journal-article","created":{"date-parts":[[2010,11,30]],"date-time":"2010-11-30T19:15:24Z","timestamp":1291144524000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":103,"title":["Quality of life and life circumstances in German myasthenia gravis patients"],"prefix":"10.1186","volume":"8","author":[{"given":"Sabine","family":"Twork","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Wiesmeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Klewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"P\u00f6hlau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Kugler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,11,11]]},"reference":[{"key":"751_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1750-1172-2-44","volume":"2","author":"V Juel","year":"2007","unstructured":"Juel V, Massey J: Myasthenia gravis. Orphanet J of Rare Dis 2007, 2: 44. 10.1186\/1750-1172-2-44","journal-title":"Orphanet J of Rare Dis"},{"key":"751_CR2","volume-title":"Neurologie","author":"KF Masuhr","year":"2007","unstructured":"Masuhr KF, Neumann M: Neurologie. 6th edition. Stuttgart: Thieme; 2007.","edition":"6"},{"key":"751_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1046\/j.1526-0968.2002.00403.x","volume":"6","author":"RM Pascuzzi","year":"2002","unstructured":"Pascuzzi RM: Myasthenia gravis and Lambert-Eaton syndrome. Ther Apher 2002, 6: 57\u201368. 10.1046\/j.1526-0968.2002.00403.x","journal-title":"Ther Apher"},{"key":"751_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1055\/s-2003-812457","volume":"72","author":"C Schneider-Gold","year":"2004","unstructured":"Schneider-Gold C, Hartung HP: Myasthenia gravis: Pathogenese, Diagnostik und Therapie. Fortschr Neurol Psychiatr 2004, 72: 45\u201357. 10.1055\/s-2003-812457","journal-title":"Fortschr Neurol Psychiatr"},{"key":"751_CR5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.nurt.2008.08.011","volume":"5","author":"R Gold","year":"2008","unstructured":"Gold R, Schneider-Gold C: Current and Future Standards in Treatment of Myasthenia Gravis. Neurotherapeutics 2008, 5: 535\u2013541. 10.1016\/j.nurt.2008.08.011","journal-title":"Neurotherapeutics"},{"key":"751_CR6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00393-009-0456-0","volume":"68","author":"W Marouf","year":"2009","unstructured":"Marouf W, Sieb JP: Myasthenia gravis und myasthene Syndrome. Z Rheumatol 2009, 68: 465\u2013470. 10.1007\/s00393-009-0456-0","journal-title":"Z Rheumatol"},{"key":"751_CR7","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/S0140-6736(00)05186-2","volume":"357","author":"A Vincent","year":"2001","unstructured":"Vincent A, Palace J, Hilton-Jones D: Myasthenia gravis. Lancet 2001, 357: 2122\u20132128. 10.1016\/S0140-6736(00)05186-2","journal-title":"Lancet"},{"key":"751_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0022-510X(00)00367-1","volume":"179","author":"RH Paul","year":"2000","unstructured":"Paul RH, Cohen RA, Gilchrist JM, Aloia MS, Goldstein JM: Cognitive dysfunction in individuals with myasthenia gravis. J Neurol Sci 2000, 179: 59\u201364. 10.1016\/S0022-510X(00)00367-1","journal-title":"J Neurol Sci"},{"key":"751_CR9","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/mus.21478","volume":"40","author":"C Marra","year":"2009","unstructured":"Marra C, Marsili F, Quaranta D, Evoli A: Determinants of cognitive impairment in elderly myasthenia gravis patients. Muscle Nerve 2009, 40: 952\u2013959. 10.1002\/mus.21478","journal-title":"Muscle Nerve"},{"key":"751_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki","year":"2000","unstructured":"Jaretzki A, Barohn R, Ernstoff R, Kaminski H, Keesey J, Penn A, Sanders D: Myasthenia gravis: Recommendations for clinical research standards. Neurology 2000, 55: 16\u201323.","journal-title":"Neurology"},{"key":"751_CR11","first-page":"497","volume":"38","author":"KE Ossermann","year":"1971","unstructured":"Ossermann KE, Genkins G: Studies in myasthenia gravis: review of a twenty-years experience in over 1200 patients. Mt Sinai J Med 1971, 38: 497\u2013537.","journal-title":"Mt Sinai J Med"},{"key":"751_CR12","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s004150050604","volume":"247","author":"F Romi","year":"2000","unstructured":"Romi F, Skeie GO, Gilhus NE: Muscle antibodies in subgroups of myasthenia gravis patients. J Neurol 2000, 247: 369\u2013375. 10.1007\/s004150050604","journal-title":"J Neurol"},{"key":"751_CR13","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1196\/annals.1405.040","volume":"1132","author":"JA Aarli","year":"2008","unstructured":"Aarli JA: Myasthenia Gravis in the Elderly. Ann NY Acad Sci 2008, 1132: 238\u2013243. 10.1196\/annals.1405.040","journal-title":"Ann NY Acad Sci"},{"key":"751_CR14","volume-title":"Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie","author":"HC Diener","year":"2008","unstructured":"Diener HC, Putzki N: Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. 4th edition. Stuttgart: Thieme; 2008.","edition":"4"},{"key":"751_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/ana.10400","volume":"53","author":"DB Drachman","year":"2003","unstructured":"Drachman DB, Jones RJ, Brodsky RA: Treatment of refractory myasthenia: \"Rebooting\" with high-dose cyclophosphamide. Ann Neurol 2003, 53: 29\u201334. 10.1002\/ana.10400","journal-title":"Ann Neurol"},{"key":"751_CR16","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1136\/jnnp.68.2.214","volume":"68","author":"A Komiyama","year":"2000","unstructured":"Komiyama A, Arai H, Kijima M, Hirayama K: Extraocular muscle responses to high dose intravenous methylprednisolone in myasthenia gravis. J Neurol Neurosurg Psychiatry 2000, 68: 214\u2013217. 10.1136\/jnnp.68.2.214","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"751_CR17","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1212\/01.WNL.0000094122.88929.0B","volume":"61","author":"MN Meriggioli","year":"2003","unstructured":"Meriggioli MN, Ciafaloni E, Al-Hayk KA, Rowin J, Tucker-Lipscomb B, Massey JM, Sanders DB: Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003, 61: 1438\u20131440.","journal-title":"Neurology"},{"key":"751_CR18","first-page":"1350","volume":"90","author":"G Rilling","year":"2001","unstructured":"Rilling G, Tettenborn B: The treatment of myasthenia gravis. Schweiz Rundsch Med Prax 2001, 90: 1350\u20131354.","journal-title":"Schweiz Rundsch Med Prax"},{"key":"751_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0303-8467(03)00046-5","volume":"106","author":"N Wakata","year":"2003","unstructured":"Wakata N, Saito T, Tanaka S, Hirano T, Oka K: Tacrolimus hydrate (FK 506): therapeutic effects and selection of responders in the treatment of myasthenia gravis. Clin Neurol Neurosurg 2003, 106: 5\u20138. 10.1016\/S0303-8467(03)00046-5","journal-title":"Clin Neurol Neurosurg"},{"key":"751_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1212\/WNL.55.1.7","volume":"55","author":"GS Gronseth","year":"2000","unstructured":"Gronseth GS, Barohn RJ: Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 55: 7\u201315.","journal-title":"Neurology"},{"key":"751_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1034\/j.1600-0404.2000.00014.x","volume":"101","author":"LC Werneck","year":"2000","unstructured":"Werneck LC, Cunha FMB, Scola RH: Myasthenia gravis: a retrospective study comparing thymectomy to conservative treatment. Acta Neurol Scand 2000, 101: 41\u201346. 10.1034\/j.1600-0404.2000.00008.x","journal-title":"Acta Neurol Scand"},{"key":"751_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1046\/j.1526-0968.2000.00183.x","volume":"4","author":"WF Haupt","year":"2000","unstructured":"Haupt WF, Rosenow F, van der Ven C, Birkmann C: Immunoadsorption in Guillain-Barr\u00e9 syndrome and myasthenia gravis. Ther Apher 2000, 4: 195\u2013197. 10.1046\/j.1526-0968.2000.00183.x","journal-title":"Ther Apher"},{"key":"751_CR23","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s004150070149","volume":"247","author":"JH Yeh","year":"2000","unstructured":"Yeh JH, Chiu HC: Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis. J Neurol 2000, 247: 510\u2013513. 10.1007\/s004150070149","journal-title":"J Neurol"},{"key":"751_CR24","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","volume":"291","author":"MC Dalakas","year":"2004","unstructured":"Dalakas MC: Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases. JAMA 2004, 291: 2367\u20132375. 10.1001\/jama.291.19.2367","journal-title":"JAMA"},{"key":"751_CR25","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/mus.1034","volume":"24","author":"RH Paul","year":"2001","unstructured":"Paul RH, Nash JM, Cohen RA, Gilchrist JM, Goldstein JM: Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve 2001, 24: 512\u2013516. 10.1002\/mus.1034","journal-title":"Muscle Nerve"},{"key":"751_CR26","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s100720100066","volume":"22","author":"L Padua","year":"2001","unstructured":"Padua L, Evoli A, Aprile I, Caliandro P, Mazza S, Padua R, Tonali P: Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci 2001, 22: 363\u2013369. 10.1007\/s100720100066","journal-title":"Neurol Sci"},{"key":"751_CR27","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/mus.21016","volume":"38","author":"LL Mullins","year":"2008","unstructured":"Mullins LL, Carpentier MY, Paul RH, Sanders DB: Disease-specific measure of quality of life for myasthenia gravis. Muscle Nerve 2008, 38: 947\u2013956. 10.1002\/mus.21016","journal-title":"Muscle Nerve"},{"key":"751_CR28","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/mus.21053","volume":"38","author":"TM Burns","year":"2008","unstructured":"Burns TM, Conaway MR, Cutter GR, Sanders DB: Less is more, or almost as much: A 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve 2008, 38: 957\u2013963. 10.1002\/mus.21053","journal-title":"Muscle Nerve"},{"key":"751_CR29","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-010-5549-9","volume":"257","author":"Y Winter","year":"2010","unstructured":"Winter Y, Schepelmann K, Spottke AE, Claus D, Grothe C, Schr\u00f6der R, Heuss D, Vielhaber S, Tackenberg B, Mylius V, Reese JP, Kiefer R, Schrank B, Oertel WH, Dodel R: Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol 2010, 257: 1473\u20131481. 10.1007\/s00415-010-5549-9","journal-title":"J Neurol"},{"key":"751_CR30","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/mus.10035","volume":"25","author":"L Padua","year":"2002","unstructured":"Padua L, Evoli A, Aprile I, Caliandro P, D'Amico P, Rabini A, Tonali P: Quality of life in patients with myasthenia gravis. Muscle Nerve 2002, 25: 466\u2013467. 10.1002\/mus.10035","journal-title":"Muscle Nerve"},{"key":"751_CR31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/01.cnd.0000202223.39994.c0","volume":"7","author":"KR Scott","year":"2006","unstructured":"Scott KR, Kothari MJ: Self-reported pain affects quality of life in myasthenia gravis. J Clin Neuromuscul Dis 2006, 7: 110\u2013114. 10.1097\/01.cnd.0000202223.39994.c0","journal-title":"J Clin Neuromuscul Dis"},{"key":"751_CR32","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1007\/s00464-008-9794-2","volume":"22","author":"K Bachmann","year":"2008","unstructured":"Bachmann K, Burkhardt D, Schreiter I, Kaifi J, Busch C, Thayssen G, Izbicki JR, Strate T: Long-term outcome and quality of life after open and thoracoscopic thymectomy for myasthenia gravis: Analysis of 131 patients. Surg Endosc 2008, 22: 2470\u20132477. 10.1007\/s00464-008-9794-2","journal-title":"Surg Endosc"},{"key":"751_CR33","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.surg.2008.11.009","volume":"145","author":"K Bachmann","year":"2009","unstructured":"Bachmann K, Burkhardt D, Schreiter I, Kaifi J, Schurr P, Busch C, Thayssen G, Izbicki JR, Strate T: Thymectomy is more effective than conservative treatment for myasthenia gravis regarding outcome and clinical improvement. Surgery 2009, 145: 392\u2013398. 10.1016\/j.surg.2008.11.009","journal-title":"Surgery"},{"key":"751_CR34","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","volume":"71","author":"DB Sanders","year":"2008","unstructured":"Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, Melms A, Nicolle MW, Solomons N, Richman DP: An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008, 71: 400\u2013406. 10.1212\/01.wnl.0000312374.95186.cc","journal-title":"Neurology"},{"key":"751_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10072-009-0167-y","volume":"31","author":"A Raggi","year":"2010","unstructured":"Raggi A, Leonardi M, Antozzi C, Confalonieri P, Maggi L, Cornelio F, Mantegazza R: Concordance between severity of disease, disability and health-related quality of life in Myasthenia gravis. Neurol Sci 2010, 31: 41\u201345. 10.1007\/s10072-009-0167-y","journal-title":"Neurol Sci"},{"key":"751_CR36","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s00415-009-5279-z","volume":"257","author":"M Leonardi","year":"2010","unstructured":"Leonardi M, Raggi A, Antozzi C, Confalonieri P, Maggi L, Cornelio F, Mantegazza R: The relationship between health, disability and quality of life in Myasthenia Gravis: Results from an Italian study. J Neurol 2010, 257: 98\u2013102. 10.1007\/s00415-009-5279-z","journal-title":"J Neurol"},{"key":"751_CR37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1477-7525-8-51","volume":"8","author":"O Garin","year":"2010","unstructured":"Garin O, Ayuso-Mateos JL, Almansa J, Nieto M, Chatterji S, Vilagut G, Alonso J, Cieza A, Svetskova O, Burger H, Racca V, Francescutti C, Vieta E, Kostanjsek N, Raggi A, Leonardi M, Ferrer M: Validation of the World Health Organization Disability Assessment Schedule (WHODAS-2) in patients with chronic diseases. Health Qual Life Outcomes 2010, 8: 51. 10.1186\/1477-7525-8-51","journal-title":"Health Qual Life Outcomes"},{"key":"751_CR38","first-page":"181","volume-title":"Focus on disability: Trends in Research and Application","author":"S Twork","year":"2008","unstructured":"Twork S, Klewer J, P\u00f6hlau D, Kugler J: Experiences with Healthcare Services and Quality of Life among German People with Myasthenia Gravis. In Focus on disability: Trends in Research and Application. Volume 2. Edited by: Kroll T. New York: Nova Science Publishers, Inc; 2008:181\u2013205."},{"key":"751_CR39","volume-title":"PhD thesis Technische Universit\u00e4t Dresden, Department Health Sciences\/Public Health","author":"L Wondzinski","year":"2009","unstructured":"Wondzinski L: Versorgungssituation von Patienten und Patientinnen mit Myasthenia gravis unter besonderer Ber\u00fccksichtigung der medizinischen Versorgung und der Lebensqualit\u00e4t in Bezug auf das Geschlecht und das Alter. PhD thesis Technische Universit\u00e4t Dresden, Department Health Sciences\/Public Health 2009."},{"key":"751_CR40","volume-title":"Fragebogen zum Gesundheitszustand (SF-36)","author":"M Bullinger","year":"1998","unstructured":"Bullinger M, Kirchberger I: Fragebogen zum Gesundheitszustand (SF-36). G\u00f6ttingen: Hogrefe Verlag; 1998."},{"issue":"Spec No 2","key":"751_CR41","first-page":"184","volume":"61","author":"U Ellert","year":"1999","unstructured":"Ellert U, Bellach BM: The SF-36 in the Federal Health Survey-description of a current normal sample. Gesundheitswesen 1999,61(Spec No 2):184\u2013190.","journal-title":"Gesundheitswesen"},{"key":"751_CR42","doi-asserted-by":"publisher","first-page":"196","DOI":"10.7326\/0003-4819-135-3-200108070-00012","volume":"135","author":"TJ Kaptchuk","year":"2001","unstructured":"Kaptchuk TJ, Eisenberg DM: Varieties of Healing. 2: A Taxonomy of Unconventional Healing Practices. Ann Intern Med 2001, 135: 196\u2013204.","journal-title":"Ann Intern Med"},{"key":"751_CR43","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/mus.10035","volume":"25","author":"L Padua","year":"2002","unstructured":"Padua L, Evoli A, Aprile I, Caliandro P, D'Amico P, Rabini A, Tonali P: Quality of life in patients with myasthenia gravis. Muscle Nerve 2002, 25: 466\u2013467. 10.1002\/mus.10035","journal-title":"Muscle Nerve"},{"key":"751_CR44","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S0008-4182(01)80063-6","volume":"36","author":"JS Weizer","year":"2001","unstructured":"Weizer JS, Lee AG, Coats DK: Myasthenia gravis with ocular involvement in older patients. Can J Ophthalmol 2001, 36: 26\u201333.","journal-title":"Can J Ophthalmol"},{"key":"751_CR45","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1196\/annals.1254.054","volume":"998","author":"R Mantegazza","year":"2003","unstructured":"Mantegazza R, Baggi F, Antozzi C, Confalonieri P, Morandi L, Bernasconi P, Andreetta F, Simoncini O, Campanella A, Beghi E, Cornelio F: Myasthenia Gravis (MG): Epidemiological Data and Prognostic Factors. Ann N Y Acad Sci 2003, 998: 413\u2013423. 10.1196\/annals.1254.054","journal-title":"Ann N Y Acad Sci"},{"key":"751_CR46","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/003693300204700604","volume":"6","author":"ME Farrugia","year":"2002","unstructured":"Farrugia ME: A limited epidemiological study of seropositive myasthenia gravis in Tayside. Scott Med J 2002, 6: 132\u2013135.","journal-title":"Scott Med J"},{"key":"751_CR47","first-page":"35","volume":"41","author":"W Rohr","year":"1991","unstructured":"Rohr W, Peter H: Behavior Analysis in Myasthenia Gravis. Psychother Psychosom Med Psychol 1991, 41: 35\u201341.","journal-title":"Psychother Psychosom Med Psychol"},{"key":"751_CR48","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/00006199-199711000-00002","volume":"46","author":"EE Gulick","year":"1997","unstructured":"Gulick EE: Correlates of Quality of Life Among Persons With Multiple Sclerosis. Nurs Res 1997, 46: 305\u2013311. 10.1097\/00006199-199711000-00002","journal-title":"Nurs Res"},{"key":"751_CR49","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1468-1331.2006.01149.x","volume":"13","author":"A Rostedt","year":"2006","unstructured":"Rostedt A, Padua L, St\u00e5lberg EV: Correlation between regional myasthenic weakness and mental aspects of quality of life. Eur J Neurol 2006, 13: 191\u2013193. 10.1111\/j.1468-1331.2006.01149.x","journal-title":"Eur J Neurol"},{"key":"751_CR50","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0003-9993(23)00011-4","volume":"74","author":"EL Lohi","year":"1993","unstructured":"Lohi EL, Lindberg C, Andersen O: Physical training effects in myasthenia gravis. Arch Phys Med Rehabil 1993, 74: 1178\u20131180.","journal-title":"Arch Phys Med Rehabil"},{"key":"751_CR51","first-page":"568","volume":"68","author":"WS Pease","year":"1987","unstructured":"Pease WS, Lagattuta FP: Exacerbation of a case of myasthenia gravis during therapeutic electric stimulation. Arch Phys Med Rehabil 1987, 68: 568\u2013570.","journal-title":"Arch Phys Med Rehabil"},{"key":"751_CR52","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2165\/00023210-200721060-00004","volume":"21","author":"IB Kulaksizoglu","year":"2007","unstructured":"Kulaksizoglu IB: Mood and anxiety disorders in patients with myasthenia gravis: aetiology, diagnosis and treatment. CNS Drugs 2007, 21: 473\u2013481. 10.2165\/00023210-200721060-00004","journal-title":"CNS Drugs"},{"key":"751_CR53","first-page":"640","volume":"64","author":"S Doering","year":"1993","unstructured":"Doering S, Henze T, Sch\u00fc\u00dfler G: Coping with myasthenia gravis. Nervenarzt 1993, 64: 640\u2013647.","journal-title":"Nervenarzt"},{"key":"751_CR54","first-page":"157","volume":"19","author":"W Rohr","year":"1992","unstructured":"Rohr W: Myasthenia gravis in the diagnostic frontier area of psychiatry. Psychiat Prax 1992, 19: 157\u2013163.","journal-title":"Psychiat Prax"},{"key":"751_CR55","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1001\/archneur.1993.00540060055018","volume":"50","author":"S Doering","year":"1993","unstructured":"Doering S, Henze T, Schussler G: Coping With Myasthenia Gravis and Implications for Psychotherapy. Arch Neurol 1993, 50: 617\u2013620.","journal-title":"Arch Neurol"},{"key":"751_CR56","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00415-009-5256-6","volume":"257","author":"K Schepelmann","year":"2010","unstructured":"Schepelmann K, Winter Y, Spottke AE, Claus D, Grothe C, Schr\u00f6der R, Heuss D, Vielhaber S, Mylius V, Kiefer R, Schrank B, Oertel WH, Dodel R: Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol 2010, 257: 15\u201323. 10.1007\/s00415-009-5256-6","journal-title":"J Neurol"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-7525-8-129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T09:51:48Z","timestamp":1685872308000},"score":1,"resource":{"primary":{"URL":"https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/1477-7525-8-129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,11]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["751"],"URL":"https:\/\/doi.org\/10.1186\/1477-7525-8-129","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,11]]},"assertion":[{"value":"1 July 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"129"}}